Adjunct Faculty are scientists or others who are employed outside of the school but have a specific, mutually beneficial role to Yale School of Medicine department programs.
Adjunct rank detailsDeborah Doroshow, MD, PhD
Assistant Professor AdjunctAbout
Copy Link
Titles
Assistant Professor Adjunct
Academic Affiliate in the History of Medicine
Biography
Deborah Doroshow is Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Adjunct Assistant Professor of the History of Medicine at the Yale University School of Medicine.
She graduated from Harvard College in 2004 with a B.A. in History and Science, where she wrote a senior thesis entitled "The Injection of Insulin Into American Psychiatry," which explored the history of insulin coma therapy for schizophrenia. It was awarded the Thomas Temple Hoopes Award for outstanding senior thesis, and a portion of it was subsequently published in the Journal of the History of Medicine and Allied Sciences.
She earned her Ph.D. in History with distinction (concentration in the History of Science and Medicine) from Yale University in December 2012, winning the Edwin W. Small prize for outstanding dissertation in American History and the Pressman Career Development Award from the American Association of the History of Medicine. Her book, Emotionally Disturbed: A History of Caring for America's Troubled Children, was published by the University of Chicago Press in 2019.
Additional historical work has included a study of bedwetting alarms and parenting practices in mid-twentieth century America (Isis, 2010) and a history of laws mandating premarital syphilis testing (Social History of Medicine, 2019). She is an active member of the American Association for the History of Medicine and enjoys mentoring clinician-historians in training.
Deborah earned her M.D. from Harvard Medical School in 2013. She completed her internship and residency in internal medicine at the Yale University School of Medicine in 2015 and her fellowship in hematology and oncology, also at Yale, in 2019. At Mount Sinai, she treats adults with lung cancer as well as adults with a variety of solid tumors as part of the Early Phase Trials Unit, where her work focuses on the DNA damage response.
Appointments
History of Medicine
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Resident
- Yale University School of Medicine (2015)
- MD
- Harvard Medical School (2013)
- PhD
- Yale University, History (2012)
- AB
- Harvard College, History and Science (2004)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-2221-9818
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Elizabeth Horn Prsic, MD
Erin Hofstatter, MD
John L Vaughn, MD, MS
Michael Cecchini, MD
Nelson LaMarche, PhD
Patricia LoRusso, DO
Lung Neoplasms
Publications
2025
Evaluating palliative care needs of early-phase clinical trial patients.
Crowley F, Zeng L, Hobensack M, Lehrman S, Afezolli D, Kelly L, Wey W, Chen J, Austin V, Easton E, Pagala A, Wu K, Lucas N, Wilk J, Marron T, Smith C, Gelfman L, Doroshow D. Evaluating palliative care needs of early-phase clinical trial patients. Journal Of Clinical Oncology 2025, 43: 12086-12086. DOI: 10.1200/jco.2025.43.16_suppl.12086.Peer-Reviewed Original ResearchConceptsPalliative careEnd-of-lifeEarly phase clinical trialsOutpatient PCReferral systemPalliative care needsSpecialty palliative careCancer type distributionPC servicesCare needsRetrospective cohort studyEvaluate demographic characteristicsPrevalent symptomsRate of constipationPC guidelinesPhysical discomfortCohort studyIncrease accessFisher's exact testPhase clinical trialsClinical trial patientsDemographic characteristicsMann-Whitney U testChi-squareCategorical variablesNeoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Feng D, Crowley F, Hapanowicz O, Venturini N, Lucas N, Wu K, Wilk J, Sadek N, Hamon P, Hennequin C, Devraj V, Thanigaimani P, Uldrick T, Miller E, Lowy I, Doroshow D, Tabrizian P, Schwartz M, Merad M, Marron T. Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16320.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsRelapse-free survivalOverall response rateAnti-PD-1Single-institution experienceResectable hepatocellular carcinomaNeoadjuvant immunotherapyHepatocellular carcinomaAdverse eventsTumor necrosisPathological responseSingle-agent anti-PD-1Early-stage hepatocellular carcinomaEarly-phase clinical trialsGrade 3 hepatitisAdvanced hepatocellular carcinomaDelay of surgerySurvival of patientsCombination immunotherapyNeoadjuvant settingAdjuvant immunotherapyResected tumorMetastatic diseaseImmunotherapy regimensNeoadjuvant nivolumabAssessing patient withdrawal in cancer clinical trials: A systematic evaluation of reasons and transparency in reporting.
Argulian A, Karol A, Paredes R, Oguntuyo K, Weintraub L, Miller J, Fujiwara Y, Joshi H, Doroshow D, Galsky M. Assessing patient withdrawal in cancer clinical trials: A systematic evaluation of reasons and transparency in reporting. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23003.Peer-Reviewed Original ResearchCitationsConceptsCancer clinical trialsOncology clinical trialsPhase III oncology clinical trialsSupportive care trialsPatient withdrawalClinical trialsLack of standard practicesPrimary cancer typeCare trialsFollow-upPatient-initiatedHigh attrition ratesPatients' intentionStandard careCONSORT diagramControl armDocumented reasonsOncology trialsAttrition ratesMedian Follow-UpTrial integrityWithdrawal reasonsConsent documentsTrial designSelection biasThe landscape and effectiveness of patient retention strategies in cancer clinical trials.
Weintraub L, Karol A, Paredes R, Argulian A, Oguntuyo K, Miller J, Fujiwara Y, Joshi H, Doroshow D, Galsky M. The landscape and effectiveness of patient retention strategies in cancer clinical trials. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23005.Peer-Reviewed Original ResearchConceptsTherapeutic cancer clinical trialsCancer clinical trialsRetention strategiesRate ratiosSupportive care trialsConfidence intervalsPatient education materialsEfficacy of current practicesBenefits of participationRandomized Controlled TrialsCare trialsClinical trialsPatient retentionReduced generalizabilityContact patientsUnivariate linear regressionInclusion criteriaPersonalized interventionsEducational materialsControlled TrialsIncreased likelihoodMulti-siteProtocol documentsSupportive careCurrent practicesFactors influencing withdrawal without a defined reason in oncology trials.
Paredes R, Karol A, Argulian A, Oguntuyo K, Weintraub L, Miller J, Fujiwara Y, Joshi H, Doroshow D, Galsky M. Factors influencing withdrawal without a defined reason in oncology trials. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23014.Peer-Reviewed Original ResearchConceptsRate ratiosImprove participant retentionSupportive care trialsPatient-level factorsCombination therapyParticipant flow diagramEnrollment sizeCare trialsSolid tumorsInterpretation of clinical trial resultsParticipant retentionIndustry-sponsored trialsPatient interactionsAssociated with significantly higher ratesInclusion criteriaMedian Follow-UpTrial enrollmentIncreased likelihoodSignificantly higher ratesMultivariate regressionClinical trial resultsMulti-siteTrial designPatient enrollmentDefinitive RTEvolving trends in Latin American oncology clinical trial sites.
Paredes R, Karol A, Markus A, Argulian A, Omori R, Fujiwara Y, Joshi H, Doroshow D, Galsky M. Evolving trends in Latin American oncology clinical trial sites. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23155.Peer-Reviewed Original ResearchConceptsPlacebo-controlled designHispanic participantsParticipant recruitmentParticipant enrollmentWorld Bank criteriaTrial sitesParticipant dataStudy evaluated trendsAntibody-drug conjugatesHealthcare infrastructureMulti-arm designPhase 3 oncology trialsHormone therapyBiologic therapyClinical trial sitesTargeted therapyPARP inhibitorsLatin America countriesTrial initiationTherapyParticipantsCancer typesSite proportionsClinical researchOncology trialsA randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.
Zhang J, Cai J, Wang H, Yu Y, Bosch-Barrera J, Bernabé R, Andric Z, Badin F, Okuma Y, Paik P, Naidoo J, Kalofonos H, Wang B, Jotte R, Pennell N, Riess J, Doroshow D, Nishio M, Alatorre-Alexander J, Lu S. A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps8664.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerProgression-free survivalFirst-line treatmentMetastatic non-small cell lung cancerCell lung cancerPD-1PD-L1Metastatic diseaseFirst-line treatment of metastatic non-small cell lung cancerLung cancerPD-L1 tumor proportion scoreTreatment of metastatic non-small cell lung cancerProgrammed cell death protein 1Cell death protein 1Programmed death-ligand 1Randomized phase 3 studyStandard first-line treatmentDevelopment of metastatic diseaseDisease control rateTumor proportion scoreDeath-ligand 1Platinum-doublet chemotherapyTargeting PD-1Duration of responseFirst-line therapyClinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population.
Argulian A, Van Hyfte G, Baldwin E, Kulshrestha A, Lucas N, Wilk J, Wu K, Yuan M, Fazilov G, Fitzgerald L, Hapanowicz O, Osorio M, Cuevas J, Wawrzyniak A, Acuna-Villaorduna A, Zamarin D, Feng D, Galsky M, Marron T, Doroshow D. Clinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population. Journal Of Clinical Oncology 2025, 43: e13514-e13514. DOI: 10.1200/jco.2025.43.16_suppl.e13514.Peer-Reviewed Original ResearchConceptsEarly phase clinical trialsOverall survivalPerformance statusAnalyze factors associated with overall survivalFactors associated with overall survivalClinical trialsDose of study therapyDistance to treatment centerUnivariate Cox proportional hazards modelSolid tumor patientsECOG performance statusRetrospective chart reviewEffective novel therapiesPhase clinical trialsCox proportional hazards modelsProportional hazards modelAssociated with decreased likelihoodNon-white raceMedian OSECOG PSStudy therapyT patientsOncology clinical trialsMedian timeTherapeutic optionsA phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.
Crowley F, Lucas N, Wu K, Wilk J, Hapanowicz O, Fitzgerald L, Park M, Rohs N, Venturini N, Yankelevitz D, Chaddha U, Harkin T, Beasley M, Nicastri D, Hakami-kermani A, Housman B, Doroshow D, Kaufman A, Merad M, Marron T. A phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC. Journal Of Clinical Oncology 2025, 43: tps2696-tps2696. DOI: 10.1200/jco.2025.43.16_suppl.tps2696.Peer-Reviewed Original ResearchConceptsResected NSCLCIL-4 signalingIL-4Potential biomarkers of responsePathologic complete response rateTumor-infiltrating myeloid cellsImmune responseResponse rateAnti-PD-1Early-stagePD-1 blockadeSafety run-inComplete response ratePathological response rateStage 1 tumorsPhase 1/2 trialEffector T cellsEvent-free survivalPre-operative treatmentStage I diseaseT cell changesBiomarkers of responseDelay of surgeryStudy of combined treatmentIL-4 receptor alphaAzenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Ma J, Liu W, Li J, Kim D, Kim S, Levy A, Cai Z, Bunker K, Recio-Boiles A, Segar J, Sen S, Doroshow D, Jandial D, Rutgard M, Harismendy O, Grant S, Samatar A, Fischer K, Lackner M. Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. Molecular Cancer Therapeutics 2025, 24: 1171-1185. PMID: 40231599, PMCID: PMC12314526, DOI: 10.1158/1535-7163.mct-24-1194.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDNA damageMaintenance of genome integrityDNA damage response networkRegulate cell cycle progressionCell cycle checkpointsAccumulation of DNA damageCell cycle progressionInduction of apoptosisAnticancer therapeutic targetSolid tumorsGenome integrityCancer cell linesReplication stressCycle progressionGenomic instabilityAntitumor activityMitotic catastropheCell cyclePreclinical efficacy modelsAdvanced solid tumorsSolid tumor indicationsPhase I studyDamaged DNATumor growth inhibitionCessation of treatment
Get In Touch
Copy Link